Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089284 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00089284 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 30 participants.
The verdict
NCT00089284, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Motexafin gadolinium may increase the effectiveness of yttrium Y 90 ibritumomab tiuxetan by making the cancer cells more sensitive to the drug. This phase I/II trial is studying the side effects and best dose of motexafin gadolinium when administered with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well they work in treating patients with stage II, stage III, or stage IV relapsed or refractory non-Hodgkin's lymphoma.
Interventions
- DRUG Rituxan
- DRUG motexafin gadolinium
- DRUG 111Indium-Zevalin and 90Yttrium-Zevalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-10-28 |
| Est. Completion | 2008-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089284
The ClinicalTrials.gov registry entry for NCT00089284 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituxan is the first listed.
NCT00089284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089284 about?
NCT00089284 is a clinical study titled "Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL". Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Motexafin gadolinium may increase the effectiveness of yttrium Y 90 ibritumomab tiuxetan b...
What is the current status of trial NCT00089284?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2003-10-28. Estimated completion is 2008-08-20.
What interventions are being tested in trial NCT00089284?
The interventions under investigation include: Rituxan (DRUG), motexafin gadolinium (DRUG), 111Indium-Zevalin and 90Yttrium-Zevalin (DRUG).
Who is sponsoring clinical trial NCT00089284?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.